WallStreetZen

NYSE: NVO
Novo Nordisk A S Earnings & Revenue

NVO past earnings growth

How has NVO's earnings growth performed historically?
Company
19.93%
Industry
8.74%
Market
38.02%
NVO's earnings have grown slower (8.41% per year) than the US Biotechnology industry average (17.81%)
Performance
NVO's earnings have grown slower (8.41% per year) than the US market average (28.47%)
Performance
NVO's earnings growth is accelerating - its growth over the last year (19.93%) is above its 5-year compound annual rate (8.41%)
Performance

NVO past revenue growth

How has NVO's revenue growth performed historically?
Company
11.37%
Industry
191.21%
Market
16.24%
NVO's revenue has grown slower (4.79% per year) than the US Biotechnology industry average (126.2%)
Performance
NVO's revenue has grown slower (4.79% per year) than the US market average (16.12%)
Performance
NVO's revenue growth is accelerating - its growth over the last year (11.37%) is above its 5-year compound annual rate (4.79%)
Performance

NVO earnings and revenue history

Current Revenue
$19.5B
Current Earnings
$6.7B
Current Profit Margin
34.4%

NVO Return on equity

Current Company
74.3%
Current Industry
-9.4%
Current Market
23.9%
NVO's Return on Equity (74.3%) shows a company that is highly efficient at transforming shareholder equity into returns
Performance

NVO Return on assets

Current Company
32.6%
Current Industry
-6.9%
Current Market
6.2%
NVO is generating higher Return on Assets (32.6%) than the US Biotechnology industry average (-11.5%)
Performance

NVO Return on capital employed

Current Company
81.39%
Current Industry
2.2%
NVO's ability to generate Return on Capital (81.39%) has decreased compared to 3 years ago (96.99%)
Performance

Novo Nordisk A S Earnings & Revenue FAQ

What were NVO's earnings last quarter?

Novo Nordisk A S (NYSE: NVO) reported Q3 2020 earnings per share (EPS) of $0.67, up 6.33% year over year. Total Novo Nordisk A S earnings for the quarter were $1.59 billion. In the same quarter last year, Novo Nordisk A S's earnings per share (EPS) was $0.63.

What was NVO's revenue last quarter?

Novo Nordisk A S (NYSE: NVO) reported Q3 2020 revenue of $4.73 billion up 6.25% year over year. In the same quarter last year, Novo Nordisk A S's revenue was $4.45 billion.

What was NVO's earnings growth in the past year?

As of Q1 2021, Novo Nordisk A S's earnings has grown 19.93% year over year. This is 11.2 percentage points higher than the US Biotechnology industry earnings growth rate of 8.74%. Novo Nordisk A S's earnings in the past year totalled $6.72 billion.

What was NVO's revenue growth in the past year?

As of Q1 2021, Novo Nordisk A S's revenue has grown 11.37% year over year. This is 179.84 percentage points lower than the US Biotechnology industry revenue growth rate of 191.21%. Novo Nordisk A S's revenue in the past year totalled $19.54 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics